Cell Signaling Technology

Phospho-SMAD2 (Ser245/250/255) Antibody

#3104 · western blot · $366

60
Evidence Score · Well-Established
Used by 99 independent labs across 100 papers. How we score this →
100
Citing papers
14k
Combined citations
Supplier page Find this product

Research areas

Cancer-related molecular mechanisms research8Neurogenesis and neuroplasticity mechanisms8Epigenetics and DNA Methylation7MicroRNA in disease regulation7Endoplasmic Reticulum Stress and Disease6RNA modifications and cancer6Cancer, Hypoxia, and Metabolism5Cancer-related Molecular Pathways5

Papers citing this product

1
The Time of Prenatal Immune Challenge Determines the Specificity of Inflammation-Mediated Brain and Behavioral Pathology
Journal of Neuroscience·2006·774 cit.·DOI
2
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
The EMBO Journal·2012·772 cit.·DOI
3
RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome
Nature Communications·2017·596 cit.·DOI
4
A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice
Nature Communications·2017·520 cit.·DOI
5
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
Oncotarget·2013·397 cit.·DOI
6
Protein design and variant prediction using autoregressive generative models
Nature Communications·2021·347 cit.·DOI
7
Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling
Journal of Clinical Investigation·2003·306 cit.·DOI
8
MiR-26b, Upregulated in Alzheimer's Disease, Activates Cell Cycle Entry, Tau-Phosphorylation, and Apoptosis in Postmitotic Neurons
Journal of Neuroscience·2013·291 cit.·DOI
9
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy
Journal of Clinical Investigation·2020·248 cit.·DOI
10
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Oncotarget·2017·196 cit.·DOI

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.

Your email is never shown publicly.